Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Perospirone (SM-9018 Free Base): Mechanism, Ion Channel M...

    2026-01-30

    Perospirone (SM-9018 Free Base): Mechanism, Ion Channel Modulation, and Schizophrenia Research Utility

    Executive Summary: Perospirone (SM-9018 free base) is an orally active atypical antipsychotic agent with sub-nanomolar affinity for 5-HT2A and D2 receptors, and partial agonist activity at 5-HT1A receptors, supporting its use in schizophrenia research (DOI:10.1002/jat.4883). Recent studies reveal that Perospirone directly inhibits vascular Kv1.5 channels at micromolar concentrations, suggesting off-target cardiovascular effects. The compound's receptor and ion channel profile enables modeling of both neuropsychiatric and vascular comorbidities. Supplied by APExBIO as BA5009, it offers defined stability and use parameters for laboratory workflows (product page). Perospirone’s mechanism and translational value are clarified in the context of recent mechanistic research and protocol recommendations.

    Biological Rationale

    Schizophrenia is a chronic neuropsychiatric disorder characterized by positive, negative, and cognitive symptoms. The disorder involves dysregulation of serotonergic and dopaminergic signaling pathways in the brain (DOI:10.1002/jat.4883). Second-generation antipsychotics (SGAs), including Perospirone, are classified as serotonin–dopamine antagonists (SDAs) and are designed to target these neurotransmitter systems. Perospirone (SM-9018 free base) was developed in Japan and is primarily used in research settings to model schizophrenia and related neuropsychiatric conditions (APExBIO). Its unique receptor binding profile and emerging ion channel effects make it a valuable agent for translational studies that explore both CNS and cardiovascular endpoints. This dual utility enables researchers to examine comorbidities often seen in schizophrenia, including cardiovascular dysregulation (mechanistic insights).

    Mechanism of Action of Perospirone (SM-9018 free base)

    • 5-HT2A receptor antagonism: Perospirone binds to serotonin 5-HT2A receptors with high affinity (Ki = 0.6 nM), attenuating serotonergic excitation in cortical circuits (DOI:10.1002/jat.4883).
    • Dopamine D2 receptor antagonism: The compound exhibits strong antagonism at dopamine D2 receptors (Ki = 1.4 nM), reducing dopaminergic hyperactivity in mesolimbic pathways, a hallmark of the positive symptoms of schizophrenia (DOI).
    • Partial 5-HT1A agonism: Perospirone partially agonizes 5-HT1A receptors (Ki = 2.9 nM), which may enhance mood and cognitive outcomes and reduce extrapyramidal side effects compared to other antipsychotics (DOI).
    • Ion channel modulation: Perospirone inhibits voltage-gated Kv1.5 potassium channels in vascular smooth muscle cells with an IC50 of 20.54 ± 2.89 μM, independent of voltage sensor state, potentially affecting vascular tone (DOI).

    This combined mechanism distinguishes Perospirone from other SGAs and enables a broader spectrum of experimental endpoints. For an extended comparison, see this article, which outlines how Perospirone’s multi-modal actions go beyond traditional receptor-based frameworks in schizophrenia models.

    Evidence & Benchmarks

    • Perospirone acts as a serotonin 5-HT2A receptor antagonist with a Ki of 0.6 nM, confirming potent central serotonergic modulation (DOI:10.1002/jat.4883).
    • D2 receptor antagonism is achieved with a Ki of 1.4 nM, substantiating efficacy in attenuating positive symptoms in preclinical models (DOI).
    • Partial agonism at 5-HT1A receptors (Ki = 2.9 nM) supports reduced extrapyramidal symptomatology versus full antagonists (DOI).
    • Direct inhibition of vascular Kv1.5 channels is concentration-dependent (IC50 = 20.54 ± 2.89 μM), with no effect on activation/inactivation kinetics, and is not use-dependent (DOI).
    • Perospirone’s Kv1.5 channel block is partially mitigated by DPO-1, a selective Kv1.5 inhibitor, confirming target specificity in vascular smooth muscle (DOI).
    • The compound is supplied by APExBIO as a solid (C23H30N4O2S, MW 426.57), recommended for storage at -20°C for optimal stability (product page).
    • Perospirone is most stable in dry form; 10 mM DMSO solutions are for short-term use only (product page).
    • Shipping from APExBIO uses Blue Ice for small molecules and Dry Ice for modified nucleotides, optimizing compound stability (product page).

    This evidence base is extended by recent internal content, which further discusses translational imperatives and actionable guidance for leveraging Perospirone’s dual receptor and ion channel activity in complex neuropsychiatric models. Unlike prior reviews, this article directly connects peer-reviewed findings with standardized workflow recommendations.

    Applications, Limits & Misconceptions

    Perospirone (SM-9018 free base) is widely adopted in preclinical models of schizophrenia and related neuropsychiatric disorders. Its dual action on serotonergic and dopaminergic receptors, coupled with ion channel effects, facilitates advanced modeling of CNS and cardiovascular comorbidities. For an updated perspective on ion channel modulation in neuropsychiatric models, see this resource, which this article extends by integrating direct evidence from new peer-reviewed studies and product-standardized parameters.

    Common Pitfalls or Misconceptions

    • Perospirone is not approved for diagnostic or therapeutic use in humans outside Japan; it is intended strictly for research applications (APExBIO).
    • Long-term storage of Perospirone in solution (e.g., DMSO) is not recommended due to degradation risks; use freshly prepared solutions (product page).
    • Off-target cardiovascular effects may confound results in vascular assays; Kv1.5 inhibition should be monitored in translational workflows (DOI).
    • Perospirone’s effects are not interchangeable with other SGAs; its unique receptor and ion channel profile necessitate careful protocol design (comparative review).
    • Solution stability and shipping conditions are critical; improper handling may compromise compound integrity and reproducibility (product page).

    Workflow Integration & Parameters

    • For optimal results, store Perospirone (BA5009) at -20°C in solid form.
    • Prepare working solutions fresh at 10 mM in DMSO; discard after use to avoid degradation (product page).
    • Follow APExBIO's shipping recommendations: Blue Ice for small molecules, Dry Ice for modified nucleotides.
    • Use validated protocols for receptor binding or ion channel assays, specifying buffer, pH, and temperature.
    • Monitor for off-target Kv1.5 inhibition in cardiovascular models; consider DPO-1 as a control inhibitor for specificity checks (DOI).

    For additional strategic integration tips, see this guidance, which this article updates by providing recent peer-reviewed evidence and precise APExBIO workflow recommendations.

    Conclusion & Outlook

    Perospirone (SM-9018 free base; BA5009) is a potent, well-characterized tool for research on schizophrenia and neuropsychiatric disorders. Its combined serotonin-dopamine antagonism and Kv1.5 channel inhibition enable complex, translational modeling of both CNS and cardiovascular endpoints. APExBIO’s standardized product supports reproducible workflows. As new studies clarify off-target effects, researchers should design protocols that capture both primary and secondary pharmacological actions (DOI). Ongoing research may further expand the experimental and translational utility of Perospirone in neuropsychiatric and vascular models.